High efficiency of the pan-PI3K/mTOR inhibitor, PQR-309, in MCL

被引：0
|
作者：
Kvint, R. [1 ]
Zimmermann, Y. [1 ]
Hutter, G. [1 ]
Hiddemann, W. [1 ]
Dreyling, M. [1 ]
机构：
[1] Klinikum Univ Munchen, Med Klin 3, Munich, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2016年 / 39卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P524
引用
收藏
页码：153 / 154
页数：2
相关论文
共 50 条
  • [31] Brain-penetrant PQR620 mTOR and PQR530 PI3K/mTOR inhibitor reduce huntingtin levels in cell models of HD
    Singer, Elisabeth
    Walter, Carolin
    Fabbro, Doriano
    Rageot, Denise
    Beaufils, Florent
    Wymann, Matthias P.
    Rischert, Nadine
    Riess, Olaf
    Hillmann, Petra
    Huu Phuc Nguyen
    NEUROPHARMACOLOGY, 2020, 162
  • [32] Modulation of Platelet Activation and Thrombus Formation Using a Pan-PI3K Inhibitor S14161
    Yi, Wenxiu
    Li, Qiang
    Shen, Jian
    Ren, Lijie
    Liu, Xiaohui
    Wang, Qi
    He, Sudan
    Wu, Qingyu
    Hu, Hu
    Mao, Xinliang
    Zhu, Li
    PLOS ONE, 2014, 9 (08):
  • [33] NVP-BEZ235, a dual pan-PI3K/mTOR kinase inhibitor, is effective in human lung cancer models harboring EGFR mutations
    Schnell, C. R.
    Vaxelaire, J.
    Vogelsanger, M.
    Hattenberger, M.
    Stauffer, F.
    Arnal, S.
    Garcia-Echeverria, C.
    Maira, S. M.
    EJC SUPPLEMENTS, 2008, 6 (12): : 69 - 69
  • [34] Final results of the pharmacodynamic (PD) data of PQR309-001 a first-in-human trial of a combined PI3K/mTOR inhibitor in advanced solid tumors
    Wicki, Andreas
    Pretre, Vincent
    Ritschard, Reto
    Brown, Nicholas
    Bize, Vincent
    Fabbro, Thomas
    Cmiljanovic, Natasa
    Dimitrijevic, Sasa
    Schmitz, Deborah
    Stumm, Michael
    Kristeleit, Rebecca
    CANCER RESEARCH, 2016, 76
  • [35] Phase I Study of the Pan-PI3K Inhibitor Buparlisib in Adult Chinese Patients with Advanced Solid Tumors
    Wu, Yi-Long
    Zhang, Li
    Trandafir, Lucia
    Dong, Tuochuan
    Duval, Vincent
    Hazell, Katharine
    Xu, Binghe
    ANTICANCER RESEARCH, 2016, 36 (11) : 6185 - 6194
  • [36] Suppression of PI3K/Akt/mTOR/c-Myc/mtp53 Positive Feedback Loop Induces Cell Cycle Arrest by Dual PI3K/mTOR Inhibitor PQR309 in Endometrial Cancer Cell Lines
    Hsin, I-Lun
    Shen, Huang-Pin
    Chang, Hui-Yi
    Ko, Jiunn-Liang
    Wang, Po-Hui
    CELLS, 2021, 10 (11)
  • [37] B591, a novel specific pan-PI3K inhibitor, preferentially targets cancer stem cells
    Hongyu Zhou
    Chunlei Yu
    Lingmei Kong
    Xiaoliang Xu
    Juming Yan
    Yingchao Li
    Tao An
    Liang Gong
    Yaxiao Gong
    Huifang Zhu
    Hongbin Zhang
    Xiaodong Yang
    Yan Li
    Oncogene, 2019, 38 : 3371 - 3386
  • [38] Potential antitumor effect of a pan-PI3K inhibitor ZSTK474 on human sarcoma cell lines
    Dan, Shingo
    Tamaki, Naomi
    Namatame, Nachi
    Yoshizawa, Yuya
    Okamura, Mutsumi
    Nishimura, Yumiko
    Yamazaki, Kanami
    Yaguchi, Shin-ichi
    CANCER RESEARCH, 2019, 79 (13)
  • [39] B591, a novel specific pan-PI3K inhibitor, preferentially targets cancer stem cells
    Zhou, Hongyu
    Yu, Chunlei
    Kong, Lingmei
    Xu, Xiaoliang
    Yan, Juming
    Li, Yingchao
    An, Tao
    Gong, Liang
    Gong, Yaxiao
    Zhu, Huifang
    Zhang, Hongbin
    Yang, Xiaodong
    Li, Yan
    ONCOGENE, 2019, 38 (18) : 3371 - 3386
  • [40] Pharmacokinetics and pharmacodynamic biomarkers for the pan-PI3K inhibitor GDC-0941: Initial Phase I evaluation
    LoRusso, P.
    Sarker, D.
    Von Hoff, D.
    Tibes, R.
    Derynck, M. K.
    Ware, J. A.
    Yan, Y.
    Demetri, G. D.
    de Bono, J. S.
    Wagner, A. J.
    EJC SUPPLEMENTS, 2008, 6 (12): : 70 - 71
12345